Literature DB >> 21336826

Polycomb and the emerging epigenetics of pancreatic cancer.

Adrienne Grzenda1, Tamas Ordog, Raul Urrutia.   

Abstract

INTRODUCTION: The revolution of epigenetics has revitalized cancer research, shifting focus away from somatic mutation toward a more holistic perspective involving the dynamic states of chromatin. Disruption of chromatin organization can directly and indirectly precipitate genomic instability and transformation. DISCUSSION: One group of epigenetic mediators, the Polycomb group (PcG) proteins, establishes heritable gene repression through methylation of histone tails. Although classically considered regulators of development and cellular differentiation, PcG proteins engage in a variety of neoplastic processes, including cellular proliferation and invasion. Due to their multifaceted potential, PcG proteins rest at the intersection of transcriptional memory and malignancy. Expression levels of PcG proteins hold enormous diagnostic and prognostic value in breast, prostate, and more recently, gastrointestinal cancers.
CONCLUSION: In this review, we briefly summarize the function of PcG proteins and report the latest developments in understanding their role in pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21336826      PMCID: PMC3678558          DOI: 10.1007/s12029-011-9262-4

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  118 in total

Review 1.  SET domain proteins modulate chromatin domains in eu- and heterochromatin.

Authors:  T Jenuwein; G Laible; R Dorn; G Reuter
Journal:  Cell Mol Life Sci       Date:  1998-01       Impact factor: 9.261

2.  Bmi-1 is related to proliferation, survival and poor prognosis in pancreatic cancer.

Authors:  Wenjie Song; Kaishan Tao; Haimin Li; Chen Jin; Zhenshun Song; Jun Li; Hai Shi; Xiao Li; Zheng Dang; Kefeng Dou
Journal:  Cancer Sci       Date:  2010-03-24       Impact factor: 6.716

3.  Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.

Authors:  M Schutte; R H Hruban; J Geradts; R Maynard; W Hilgers; S K Rabindran; C A Moskaluk; S A Hahn; I Schwarte-Waldhoff; W Schmiegel; S B Baylin; S E Kern; J G Herman
Journal:  Cancer Res       Date:  1997-08-01       Impact factor: 12.701

4.  Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A.

Authors:  Tiziana Tonini; Luigi Bagella; Giuseppina D'Andrilli; Pier Paolo Claudio; Antonio Giordano
Journal:  Oncogene       Date:  2004-06-17       Impact factor: 9.867

5.  Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2.

Authors:  Andrei V Ougolkov; Vladimir N Bilim; Daniel D Billadeau
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

6.  Activated p53 suppresses the histone methyltransferase EZH2 gene.

Authors:  Xiaohu Tang; Michael Milyavsky; Igor Shats; Neta Erez; Naomi Goldfinger; Varda Rotter
Journal:  Oncogene       Date:  2004-07-29       Impact factor: 9.867

7.  Bmi-1 regulates the Ink4a/Arf locus to control pancreatic beta-cell proliferation.

Authors:  Sangeeta Dhawan; Shuen-Ing Tschen; Anil Bhushan
Journal:  Genes Dev       Date:  2009-04-15       Impact factor: 11.361

8.  Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.

Authors:  Yiwei Li; Timothy G VandenBoom; Dejuan Kong; Zhiwei Wang; Shadan Ali; Philip A Philip; Fazlul H Sarkar
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

9.  MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 modification in cancer cells.

Authors:  Norishige Yamada; Yukari Nishida; Hideaki Tsutsumida; Tomofumi Hamada; Masamichi Goto; Michiyo Higashi; Mitsuharu Nomoto; Suguru Yonezawa
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

10.  Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays.

Authors:  Margarita Sánchez-Beato; Esther Sánchez; Joaquín González-Carreró; Manuel Morente; Ana Díez; Lydia Sánchez-Verde; María Carmen Martín; Juan C Cigudosa; Miguel Vidal; Miguel A Piris
Journal:  Mod Pathol       Date:  2006-05       Impact factor: 7.842

View more
  8 in total

1.  Intrinsically disordered chromatin protein NUPR1 binds to the C-terminal region of Polycomb RING1B.

Authors:  Patricia Santofimia-Castaño; Bruno Rizzuti; Ángel L Pey; Philippe Soubeyran; Miguel Vidal; Raúl Urrutia; Juan L Iovanna; José L Neira
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-18       Impact factor: 11.205

2.  Potential epigenetic mechanism(s) associated with the persistence of psychoneurological symptoms in women receiving chemotherapy for breast cancer: a hypothesis.

Authors:  Debra Lyon; Lynne Elmore; Noran Aboalela; Jacqueline Merrill-Schools; Nancy McCain; Angela Starkweather; R K Elswick; Colleen Jackson-Cook
Journal:  Biol Res Nurs       Date:  2013-04-11       Impact factor: 2.522

Review 3.  Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis.

Authors:  Angela L McCleary-Wheeler; Gwen A Lomberk; Frank U Weiss; Günter Schneider; Muller Fabbri; Tara L Poshusta; Nelson J Dusetti; Sandra Baumgart; Juan L Iovanna; Volker Ellenrieder; Raul Urrutia; Martin E Fernandez-Zapico
Journal:  Cancer Lett       Date:  2012-10-13       Impact factor: 8.679

Review 4.  Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects.

Authors:  Daniel Neureiter; Tarkan Jäger; Matthias Ocker; Tobias Kiesslich
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

5.  YY1 regulates melanoma tumorigenesis through a miR-9 ~ RYBP axis.

Authors:  Guowei Zhao; Qiang Li; Aiqin Wang; Jian Jiao
Journal:  J Exp Clin Cancer Res       Date:  2015-06-24

Review 6.  EZH2 in Bladder Cancer, a Promising Therapeutic Target.

Authors:  Mónica Martínez-Fernández; Carolina Rubio; Cristina Segovia; Fernando F López-Calderón; Marta Dueñas; Jesús M Paramio
Journal:  Int J Mol Sci       Date:  2015-11-13       Impact factor: 5.923

Review 7.  Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?

Authors:  Elisabeth Hessmann; Steven A Johnsen; Jens T Siveke; Volker Ellenrieder
Journal:  Gut       Date:  2016-11-03       Impact factor: 23.059

8.  Polycomb group proteins in cancer: multifaceted functions and strategies for modulation.

Authors:  Sijie Wang; Sandra C Ordonez-Rubiano; Alisha Dhiman; Guanming Jiao; Brayden P Strohmier; Casey J Krusemark; Emily C Dykhuizen
Journal:  NAR Cancer       Date:  2021-10-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.